{"nctId":"NCT00236197","briefTitle":"E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers","startDateStruct":{"date":"2005-10"},"conditions":["Heartburn"],"count":619,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: rabeprazole sodium"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"rabeprazole sodium","otherNames":["Aciphex"]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n1. Male or female patients \\> 18 years of age.\n2. If female, not of childbearing potential by reason of surgery or menopause, or of childbearing potential, but using an approved method of contraception since the last menstrual period. Females of childbearing potential must have a negative serum pregnancy test before starting the study.\n3. Patients must report a history of heartburn at least two days per week over the past month.\n\nKey Exclusion Criteria:\n\n1. History of erosive esophagitis verified by endoscopy.\n2. History of gastroesophageal reflux disease (GERD) diagnosed by a physician.\n3. Patients who have a history of Barrett's esophagus or esophageal stricture.\n4. Evidence of any medical condition that may interfere with the conduct of the study, the interpretation of study results, or the health of the patient during the study.\n5. Patients who require continuous use of proton pump inhibitors, histamine receptor (H2) blockers, or prokinetics. Prior intermittent use of these agents is permitted if they are discontinued at least three days prior to the run-in phase. The H2 blocker, cimetidine (TagametÂ®), must be discontinued for at least seven days before the study drug is administered.","healthyVolunteers":false,"sex":"ALL","minimumAge":"19 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Complete Heartburn Relief During the First Full 24-Hour Period in Intent-to-Treat (ITT) Population","description":"The difference in complete relief within the first 24 hours between treatment and placebo in ITT was tested using a continuity corrected chi-square test withput adjustment for baseline severity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"121","spread":null}]}]}]},{"type":"SECONDARY","title":"Summary of Percentage of Heartburn-Free Daytimes","description":"comparison between placebo and treatment will be analyzed using two-sample t-test.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[]},{"type":"SECONDARY","title":"Summary of Percentage of Heartburn-Free Nighttimes","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[]},{"type":"SECONDARY","title":"Change From Baseline in Average Regurgitation Severity Score Between Placebo and Rabeprazole","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[]},{"type":"SECONDARY","title":"Change From Baseline in Average Belching Severity Score Between Placebo and Rabeprazole","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":312},"commonTop":["Upper respiratory tract infection"]}}}